Targeted lipid nanoparticles distributed in hydrogel treat osteoarthritis by modulating cholesterol metabolism and promoting endogenous cartilage regeneration DOI Creative Commons
Zhibo Zhao, Peng Wang,

Ziyang Li

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Dec. 20, 2024

Osteoarthritis (OA) is the most common disease in aging joints and has characteristics of cartilage destruction inflammation. It currently considered a metabolic disease, CH25H-CYP7B1-RORα axis cholesterol metabolism chondrocytes plays crucial catabolic regulatory role its pathogenesis. Targeting this may provide therapeutic approach for OA treatment. Here, study, we propose to use combination stem cell-recruiting hydrogels lipid nanoparticles (LNPs) that modulate jointly promote regenerative microenvironment. Specifically, first developed an injectable, bioactive hydrogel composed self-assembling peptide nanofibers recruits endogenous synovial cells (SMSCs) promotes their chondrogenic differentiation. At same time, LNPs regulate are incorporated into slowly released, thereby improving inflammatory environment OA. Enhancements were noted conditions associated with OA, alongside successful attraction mesenchymal (MSCs) from membrane. These then observed differentiate chondrocytes, contributing effective restoration chondrocyte regeneration, offering promising In summary, provides feasible siRNA-based option, potential nonsurgical solution treatment

Language: Английский

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications DOI Creative Commons
Yingying Shi,

Miaoyuan Shi,

Yì Wáng

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Nov. 14, 2024

Abstract In the last decade, messenger ribonucleic acid (mRNA)-based drugs have gained great interest in both immunotherapy and non-immunogenic applications. This surge can be largely attributed to demonstration of distinct advantages offered by various mRNA molecules, alongside rapid advancements nucleic delivery systems. It is noteworthy that immunogenicity presents a double-edged sword. context immunotherapy, extra supplementation adjuvant generally required for induction robust immune responses. Conversely, non-immunotherapeutic scenarios, activation unwanted considering host tolerability high expression demand mRNA-encoded functional proteins. Herein, mainly focused on linear non-replicating mRNA, we overview preclinical clinical progress prospects medicines encompassing vaccines other therapeutics. We also highlight importance focusing host-specific variations, including age, gender, pathological condition, concurrent medication individual patient, maximized efficacy safety upon administration. Furthermore, deliberate potential challenges may encounter realm disease treatment, current endeavors improvement, as well application future advancements. Overall, this review aims present comprehensive understanding mRNA-based therapies while illuminating prospective development drugs.

Language: Английский

Citations

13
Why Do Lipid Nanoparticles Target the Liver? Understanding of Biodistribution and Liver-Specific Tropism DOI Creative Commons
Mahboubeh Hosseini-Kharat, Kristen E. Bremmell, Clive A. Prestidge

et al.

Molecular Therapy — Methods & Clinical Development, Journal Year: 2025, Volume and Issue: 33(1), P. 101436 - 101436

Published: Feb. 16, 2025

Lipid nanoparticles (LNPs) are now highly effective transporters of nucleic acids to the liver. This liver-specificity is largely due their association with certain serum proteins, most notably apolipoprotein E (ApoE), which directs them liver cells by binding low-density lipoprotein (LDL) receptors on hepatocytes. The liver's distinct anatomy, its various specialized cell types, also influences how LNPs taken up from circulation, cleared, and they in delivering treatments. In this review, we consider factors that facilitate LNP's targeting explore latest advances liver-targeted LNP technologies. Understanding targeted can help for design optimization nanoparticle-based therapies. Comprehension cellular interaction biodistribution not only leads better treatments diseases but delivers insight directing other tissues, potentially broadening range therapeutic applications.

Language: Английский

Citations

1
Advances in Lipid Nanoparticle‐Based Disease Treatment DOI Open Access
Yujie Zhou,

Qiqi Ge,

Xin Wang

et al.

ChemMedChem, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 17, 2025

Abstract Lipid nanoparticles (LNPs) have emerged as a transformative platform for the targeted delivery of therapeutic agents, revolutionizing treatment paradigms across spectrum diseases. Since inception liposomes in 1960s, lipid‐based nanotechnology has evolved to address limitations such poor bioavailability, off‐target effects, and instability, thereby enhancing efficacy safety drug administration. This review highlights latest advancements LNPs technology, focusing on their application cancer therapy, gene infectious disease management, glaucoma, other clinical areas. Recent studies underscore potential deliver messenger RNA (mRNA) small interfering (siRNA) precise genetic intervention, exemplified by breakthroughs interference CRISPR‐Cas9 genome editing. Additionally, been successfully employed ameliorate conditions, demonstrating versatility addressing both acute chronic disorders. However, challenges persist concerning large‐scale manufacturing, long‐term stability, comprehensive evaluations. Future research must focus optimizing formulations, exploring synergistic combinations with existing therapies, expanding scope treatable The integration into personalized medicine exploration applications diseases represent promising avenues further investigation. are poised play an increasingly central role development next‐generation therapeutics.

Language: Английский

Citations

1
Comprehensive insights of etiological drivers of hepatocellular carcinoma: Fostering targeted nano delivery to anti-cancer regimes DOI
Dipanjan Ghosh, Aharna Guin, Ashok Kumar

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189318 - 189318

Published: April 1, 2025

Language: Английский

Citations

1
In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines DOI Open Access
Sikun Meng,

Tomoaki Hara,

Yutaka Miura

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3119 - 3119

Published: March 28, 2025

Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized cancer immunotherapy but continues to face significant challenges that limit its broader application, such as targeting, the tumor microenvironment, and persistence, especially in solid tumors. Meanwhile, global implementation of mRNA vaccines during COVID-19 pandemic highlighted transformative potential lipid nanoparticle (LNP) technologies. These innovations, characterized by their swift development timelines, precise design, efficient delivery mechanisms, provide a promising framework address some limitations CAR-T therapy. Recent advancements, including mRNA-based CAR engineering optimized LNP delivery, have demonstrated capacity enhance efficacy, particularly context This review explores how mRNA-LNP technology can drive vivo engineered therapies current discusses future directions, advancements optimization, strategies for improving functionality safety. By bridging these technological insights, may evolve into versatile accessible treatment paradigm across diverse oncological landscapes.

Language: Английский

Citations

0
Targeted lipid nanoparticles distributed in hydrogel treat osteoarthritis by modulating cholesterol metabolism and promoting endogenous cartilage regeneration DOI Creative Commons
Zhibo Zhao, Peng Wang,

Ziyang Li

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Dec. 20, 2024

Osteoarthritis (OA) is the most common disease in aging joints and has characteristics of cartilage destruction inflammation. It currently considered a metabolic disease, CH25H-CYP7B1-RORα axis cholesterol metabolism chondrocytes plays crucial catabolic regulatory role its pathogenesis. Targeting this may provide therapeutic approach for OA treatment. Here, study, we propose to use combination stem cell-recruiting hydrogels lipid nanoparticles (LNPs) that modulate jointly promote regenerative microenvironment. Specifically, first developed an injectable, bioactive hydrogel composed self-assembling peptide nanofibers recruits endogenous synovial cells (SMSCs) promotes their chondrogenic differentiation. At same time, LNPs regulate are incorporated into slowly released, thereby improving inflammatory environment OA. Enhancements were noted conditions associated with OA, alongside successful attraction mesenchymal (MSCs) from membrane. These then observed differentiate chondrocytes, contributing effective restoration chondrocyte regeneration, offering promising In summary, provides feasible siRNA-based option, potential nonsurgical solution treatment

Language: Английский

Citations

2